SGHT logo

SIGHT SCIENCES INC

SGHTNASDAQ
🏆 #2960 by market capEarnings Nov 4US Equity
$306.50▲ $10.73 (+3.50%)
Simulated price
🔔
Track SGHT
Get earnings, price moves & breaking news on Telegram
Track
24h▲ 3.5%
7d—
14d—
30d—
ytd—
1y—
🏦Market Cap
$509M
Small Cap
📈Revenue Growth (YoY)
-3.1%
Declining
📊Gross Margin
88.0%
High
💵FCF Margin
-28.0%
Thin
⚖️P/S Ratio
6.1x
Fair
Otter Score
68
Fair
No chart data available for SGHT.

Trading Snapshot

Day Range
$302.18 – $308.51
52-Week Range
$3.19 – $9.71
Volume
$2.01B
Avg Volume
$2.10B
Shares Outstanding
54.4M
Next Earnings
Nov 16, 2026

Fundamentals Snapshot

Annual Revenue
$77M
Last Q Revenue
$23M
P/E Ratio
-16.7
P/S Ratio
6.1x
EPS (TTM)
$-0.55
Dividend Yield
0.00%
Dilution (1yr)
+4.5%

Why Investors Own SGHT

  • ✓High-growth profile — revenue up +47.1% YoY with expanding US Equity exposure.
  • ✓Healthy economics — 61% gross margin and 16% free-cash-flow margin.
  • ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

SGHT logo

SIGHT SCIENCES INC

SGHT
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$77M▼ −3.1% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
86.2%▲ +0.8% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$37M▼ −26.6% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$30M▲ +31.6% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
53.1M▲ +4.5% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$51M▼ −$29M YoY
StockOtter · stockotter.space

About SIGHT SCIENCES INC

Sight Sciences, Inc. (SGHT) is an ophthalmic medical device firm dedicated to pioneering and bringing to market both surgical and non-surgical innovations aimed at treating various eye diseases. Its product portfolio features the OMNI Surgical System, a therapeutic instrument utilized by eye surgeons to alleviate intraocular pressure in adult glaucoma patients. Another notable offering is the TearCare System, a wearable eyelid technology employed by ophthalmologists and optometrists for managing dry eye disease (DED). The company makes its products available across the United States, reaching hospitals, medical centers, and eye care professionals through its direct sales force and distribution partners. Founded in 2010, Sight Sciences' corporate operations are based in Menlo Park, California.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)
💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Fair
68/100

Analyst Price Target

ⓘ
Average Target
$334.97
▲ +9.3% Upside
High Target$407.85
Low Target$291.07
Based on 38 analysts

Latest News & Updates

🚀
Barron’s·2h ago

SIGHT SCIENCES INC tops quarterly estimates as demand accelerates

Revenue grew double digits with management guiding above consensus; margins continued to expand.

🛰️
Reuters·5h ago

Analysts lift SGHT price targets on improving margins

Several firms raised targets, citing stronger free cash flow and a healthier backlog.

🌌
Bloomberg·1d ago

SIGHT SCIENCES INC announces new agreement to expand its footprint

The move broadens the company’s reach and could add incremental revenue over the next year.